Attached files
| file | filename |
|---|---|
| EX-10.8 - EX-10.8 - Radius Health, Inc. | a16-6577_1ex10d8.htm |
| EX-10.2 - EX-10.2 - Radius Health, Inc. | a16-6577_1ex10d2.htm |
| EX-10.9 - EX-10.9 - Radius Health, Inc. | a16-6577_1ex10d9.htm |
| EX-31.1 - EX-31.1 - Radius Health, Inc. | a16-6577_1ex31d1.htm |
| EX-10.1 - EX-10.1 - Radius Health, Inc. | a16-6577_1ex10d1.htm |
| EX-10.4 - EX-10.4 - Radius Health, Inc. | a16-6577_1ex10d4.htm |
| EX-10.10 - EX-10.10 - Radius Health, Inc. | a16-6577_1ex10d10.htm |
| EX-10.7 - EX-10.7 - Radius Health, Inc. | a16-6577_1ex10d7.htm |
| EX-10.12 - EX-10.12 - Radius Health, Inc. | a16-6577_1ex10d12.htm |
| EX-31.2 - EX-31.2 - Radius Health, Inc. | a16-6577_1ex31d2.htm |
| EX-10.13 - EX-10.13 - Radius Health, Inc. | a16-6577_1ex10d13.htm |
| 10-Q - 10-Q - Radius Health, Inc. | a16-6577_110q.htm |
| EX-10.5 - EX-10.5 - Radius Health, Inc. | a16-6577_1ex10d5.htm |
| EX-10.6 - EX-10.6 - Radius Health, Inc. | a16-6577_1ex10d6.htm |
| EX-10.11 - EX-10.11 - Radius Health, Inc. | a16-6577_1ex10d11.htm |
| EX-32.1 - EX-32.1 - Radius Health, Inc. | a16-6577_1ex32d1.htm |
Exhibit 10.3
Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2
Statement of Work
To the Agreement between RADIUS HEALTH, INC. (“RADIUS”) and LONZA Sales AG dated 16 of October 2007
Supplemental analytical services
|
Number |
|
RDS-001-SC005 |
|
|
|
Product Code/Name |
|
RDS-001 Abaloparatide |
|
|
|
Description of the proposed change: |
|
Manufacturing of an RS solution and supply of 60 extra vials to Vetter. These vials will be produced together with the 60 vials already ordered (PO# 03329) | ||
|
Price Agreed |
|
[*]€ |
|
|
|
Radius |
|
Name: Naveen Palwai |
|
Date : 17 Mar 2016 |
|
Radius |
|
Name: Wajiha Khan |
|
Date : March 17, 2016 |
|
Lonza Sales AG |
|
Name : Paul Tastenhoye |
|
Date: 17/03/2016 |
|
Lonza Sales AG |
|
Name : Frederique Mutterer |
|
Date : 17/03/2016 |
Additional notes: /
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2
Detailed description of the proposed change
Manufacturing of an RS solution and supply of 60 extra vials to Vetter. These vials will be produced together with the 60 vials already ordered (PO# 03329)
Timescale
By mid-May.
Price and Terms of Payment
1. Price
· [*]€
2. Payment
100% upon completion
oooOOOooo
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.